Skip to main content
Sign In
 

Daniel Christoph, M.D., Ph.D.- Publications & Abstracts


2012

Publications​

Christoph DC, Hoffmann AC, Gauler TC, Reyna Asuncion B, Loewendick H, Peglow A, Hassa B, Tran C, Wynes MW, Schuler M, Eberhardt WEE, Hirsch FR
Detection of circulating lung cancer cells with strong TS-reasctivity in the peripheral blood of patient with pulmonary adenocarcinoma treated with pemetrexed.
J Thorac Oncol. 2012 Apr;7(4):766-7 PMID:22425929

Wynes MW, Konopa K, Singh S, Asuncion BR, Ranger-Moore J, Sternau A, Christoph DC, Dziadziuszko R, Jassem J, Hirsch FR
Thymidylate Synthase protein expression by IHC and gene copy number by SISH correlate and show great variability in non-small cell lung cancer.
J Thorac Oncol.

Abstracts

Christoph DC, Reyna Asuncion B, Wynes MW, Gauler TC, Wohlschlaeger J, Theegarten D, Welter S, Tran C, Hassan B, Loewendick H, Peglow A, Schuler M, Eberhardt WEE, Hirsch FR. Folylpoly-γ-glutamate synthetase and thymidylate synthase are associated with clinical outcome from pemetrexed-based therapy in advanced non-small cell lung cancer (NSCLC). Abstract 1713 Poster presentation at the AACR Annual Meeting. March 31 - April 3, 2012, Chicago, IL, USA.

Christoph DC, Reyna Asuncion B, Wynes MW, Gauler TC, Wohlschlaeger J, Theegarten D, Welter S, Tran C, Hassan B, Loewendick H, Peglow A, Schuler M, Eberhardt WEE, Hirsch FR. Folylpoly-glutamate synthetase and thymidylate synthase are associated with clinical outcome from pemetrexed-based therapy in advanced non-small cell lung cancer (NSCLC). Poster B6. Poster presentation at the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer: Biology, Therapy, and Personalized Medicine. January 8-11, 2012, San Diego, CA, USA.

2011

Abstracts 

Christoph DC, Mascaux C, Wynes MW, Reyna Asuncion B, Wohlschlaeger J, Theegarten D, Gauler TC, Schuler M, Eberhardt WEE, Hirsch FR.
Predictive value of thymidylate synthase and folylpoly-glutamate synthetase for clinical benefit from pemetrexed in malignant pleural mesothelioma.
J Clin Oncol 29: 2011 (suppl; abstr 7024).

Christoph DC
,  Wohlschlaeger J, Neumann V, Gauler TC, Poettgen C, Peglow A, Tannapfel A, Schuler M, Hirsch FR, Eberhardt WEE, Theegarten D.
Impact of dihydrofolate reductase expression for clinical benefit from pemetrexed in malignant pleural mesothelioma.
J Thorac Oncol 6: 2011 (suppl 2; abstr 1.853). 

Christoph DC
, Kasper S, Gauler TC, Breitenbuecher F, Engelhard M, Theegarten D, Poettgen C, Hepp R,  Peglow A, Loewendick H, Schuler M, Hirsch FR, Eberhardt WEE, Wohlschlaeger J.
Evaluation of betaV-tubulin expression as novel predictive biomarker for clinical benefit from treatment with taxanes in non-small cell lung cancer.
J Thorac Oncol 6: 2011 (suppl 2; abstr 2.227). |

Christoph DC
, Mascaux C, Wynes MW, Reyna Asuncion B, Wohlschlaeger J, Theegarten D, Gauler TC, Neumann V, Poettgen C, Tran C, Tannapfel A, Schuler M, Eberhardt WEE, Hirsch FR.
Predictive value of thymidylate synthase and folylpoly-glutamate synthetase for clinical benefit from pemetrexed in malignant pleural mesothelioma.
J Thorac Oncol 6: 2011 (suppl 2; abstr 2.480). 

Christoph DC
, Kasper S, Gauler TC, Breitenbuecher F, Engelhard M, Theegarten D, Poettgen C, Hepp R,  Peglow A, Loewendick H, Schuler M, Hirsch FR, Eberhardt WEE, Wohlschlaeger J.
Evaluation of betaV-tubulin expression as novel predictive biomarker for clinical benefit from treatment with taxanes in non-small cell lung cancer.
Eur J Cancer 47: 2011 (suppl 4; abstr PP35).

 

 

 

 

 

 

 

 

 

 

 
University of Colorado Denver

© The Regents of the University of Colorado, a body corporate. All rights reserved.

All trademarks are registered property of the University. Used by permission only.